Hutchmed (China)
HCM
New Fortress Energy
NFE
DexCom
DXCM
eBay
EBAY
Halozyme Therapeutics
HALO
US Stock MarketDetailed Quotes
INCY Incyte
- 60.430
- +0.430+0.72%
Trading Mar 19 14:15 ET
11.69BMarket Cap402.87P/E (TTM)
60.760High59.920Low857.01KVolume60.370Open60.000Pre Close51.71MTurnover0.53%Turnover Ratio402.87P/E (Static)193.52MShares83.95052wk High3.39P/B9.75BFloat Cap50.35052wk Low--Dividend TTM161.32MShs Float153.150Historical High--Div YieldTTM1.40%Amplitude1.850Historical Low60.340Avg Price1Lot Size
Incyte News
Express News | FOMC Projects Lower GDP and Uncertainty, No Rate Change
Fed Dot Plot in Full View as Market Holds on a Higher Note: Live Stock News
Incyte Price Target Lowered to $72 From $74 at Truist
Director's Major Stock Sale Shakes Up Incyte!
Incyte Corp. Stock Slips 3.2%, Underperforms Market
INCY Stock Down on Disappointing Skin Disease Study Data
Incyte's Povorcitinib Shows Promise but Faces Competitive and Market Challenges, Leading to Hold Rating
Tesla To $320? Here Are 10 Top Analyst Forecasts For Tuesday
Express News | Incyte Shares Are Trading Lower After William Blair and Guggenheim Downgraded the Stock and Truist Securities Cut Its Price Target From $74 to $72
This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Green Gives Way to Red on Gossamer Macro Expectations: Live Stock News
Incyte Is Maintained at Hold by Truist Securities
Incyte Price Target Maintained With a $92.00/Share by Guggenheim
Express News | Truist Securities Maintains Hold on Incyte, Lowers Price Target to $72
A Quick Look at Today's Ratings for Incyte(INCY.US), With a Forecast Between $68 to $100
Incyte's Povorcitinib Letdown Brings Downgrade -- Market Talk
Incyte Cut to Market Perform From Outperform by William Blair
Incyte Analyst Ratings
Incyte's Stock Downgraded to Sell Amid Disappointing Drug Data and Market Challenges
Guggenheim Downgrades Incyte on Povorcitinib's 'Somewhat Underwhelming' Profile
